Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

TRACON Pharmaceuticals, Inc. (TCON)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.6700+0.2800 (+20.14%)
At close: 04:00PM EDT
1.6400 -0.03 (-1.80%)
After hours: 07:30PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.3900
Open1.5800
Bid1.6400 x 2200
Ask1.6800 x 900
Day's Range1.5100 - 1.7900
52 Week Range1.2430 - 7.2290
Volume524,931
Avg. Volume91,729
Market Cap32.475M
Beta (5Y Monthly)1.77
PE Ratio (TTM)N/A
EPS (TTM)-1.5950
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.38
  • GlobeNewswire

    TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference

    SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with life science companies through a profit-share, revenue share, or franchise model, today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate in a

  • GlobeNewswire

    TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

    SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with life science companies through a profit-share, revenue share, or franchise model, today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporat

  • GlobeNewswire

    TRACON Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

    SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with companies to develop and commercialize innovative products in the U.S., today announced financial results for the first quarter ended March 31, 2022. The Company will host a conference call

Advertisement
Advertisement